The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies.
In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective of this review is to describe new developments in targeted treatments and immunotherapies for patients with both clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging avenues of RCC treatment that show considerable promise.
Written by:
Xu KY, Wu S. Are you the author?
Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY USA; Division of Hematology/Oncology, Department of Medicine, Stony Brook University School of Medicine, Room: HSC 15-053E, Stony Brook, NY USA; Northport VA Medical Center, Northport, NY USA.
Reference: Biomark Res. 2015 Mar 2;3:5.
doi: 10.1186/s40364-015-0030-7
PubMed Abstract
PMID: 25734007